Examples include bispecific CAR-T cells designed for B cell lymphoma/leukemia and A proliferation-inducing ligand (APRIL)-based CAR-T cells simultaneously targeting both BCMA and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) in multiple myeloma (48, 49). This evidence concerns the gene TNFSF13 and B-cell non-Hodgkin lymphoma.